# Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

> **NCT04902105** · PHASE1 · COMPLETED · sponsor: **Emalex Biosciences Inc.** · enrollment: 38 (actual)

## Conditions studied

- Drug Interaction

## Interventions

- **DRUG:** ecopipam HCL
- **DRUG:** Mefenamic acid
- **DRUG:** Divalproex Sodium ER

## Key facts

- **NCT ID:** NCT04902105
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-13
- **Primary completion:** 2021-07-06
- **Final completion:** 2021-07-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-07-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902105, "Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04902105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*